TNF Inhibitor · Chimeric IgG1 Monoclonal Antibody · Originator and Biosimilar Assay Families
Infliximab Remicade® / Remsima®
Ten SHIKARI® assays support infliximab pharmacokinetic and immunogenicity research. To prevent assay selection and result interpretation from being mixed, the portfolio below separates the Remicade®-associated and Remsima®-optimised kits by REF code, specifications and quotation route.
10
SHIKARI® Kits
96
Tests per kit
3
Analytical Domains
RUO
Research Use Only
6 kits · General / reference-product family
Infliximab / Remicade® assays
Drug-level, qualitative and quantitative ADA, free/total ADA and neutralising-antibody research. QS-INFLIXI is explicitly identified as covering Remicade® and Remsima®.
4 dedicated kits · CT-P13 family
Infliximab biosimilar / Remsima® assays
Dedicated Remsima®-optimised drug-level and anti-drug antibody assays, with separate REF codes and specifications.
Scientific Background
Why Infliximab is relevant to biological-drug monitoring research
Infliximab has clinically important target biology, indication-specific dosing and measurable systemic exposure, making drug concentration and immunogenicity relevant research variables. Scientific source ↗ · EMA source ↗
Mechanism
Molecular Target & Structure
Infliximab is a chimeric IgG1 monoclonal antibody that binds soluble and transmembrane TNF-α. The page retains separate Remicade® and Remsima® assay families because analytical configuration can differ even when the active biological drug is infliximab. Source ↗
Indications
Approved Indications
EMA-authorised uses include rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis, with paediatric use in selected inflammatory-bowel-disease indications. EMA source ↗
Published Evidence
Selected Trough-Level Evidence
Published exposure–response studies report indication- and outcome-specific trough concentrations:
Paediatric Crohn’s · mucosal healing≥5 µg/mL ↗
UC · endoscopic healing≥7.5 µg/mL ↗
UC · histologic healing≥10.5 µg/mL ↗
Research-associated ranges, not universal treatment cut-offs. Values vary by endpoint, timing, assay method and population. This page is for RUO product information and does not provide clinical guidance.
SHIKARI® Kit Portfolio
Ten kits, separated by assay family
Every kit below retains its own REF code, intended analytical question and official product link. Selecting a family does not combine or average assay results.
General / Reference-Product Family · 6 Kits
Infliximab / Remicade® assays
Reference-product and general infliximab assays. QS-INFLIXI is intentionally marked as a cross-family assay because its official record covers Remicade® and Remsima®.
Drug Levels Kit
SHIKARI® Q-INFLIXI
Infliximab (Remicade®) ELISA
REF: INF-FD-REMI
Quantitative enzyme immunoassay for infliximab (Remicade®) in human serum and plasma, developed for measurements across the Cmin–Cmax research range.
Representative Standard Curve
Levels Specific Kit
SHIKARI® QS-INFLIXI
Specific Infliximab ELISA (mAb-based)
REF: INF-SPEC-INF
Specific and quantitative enzyme immunoassay for free infliximab in human serum and plasma. The official product record explicitly covers both Remicade® and Remsima®.
Representative Standard Curve
Qualitative ADA Kit
SHIKARI® Q-ATI
Anti-Infliximab (Remicade®) ELISA
REF: INF-QLS-REMI
Qualitative enzyme immunoassay for antibodies to infliximab (Remicade®) in human serum and plasma. Results are interpreted against the assay cut-off rather than as a quantitative titre.
Quantitative ADA Kit
SHIKARI® Q-ATI w/confirmation
Quantitative Anti-Infliximab (Remicade®) ELISA
REF: INF-QNS-REMI
Quantitative enzyme immunoassay for antibodies to infliximab (Remicade®) in human serum and plasma, supplied with a confirmation step.
Representative Standard Curve
Free / Total ADA Kit
SHIKARI® Q-ATI TOTAL
Free/Total Anti-Infliximab ELISA
REF: INF-QNFT-REMI
Semi-quantitative assay for total and free antibodies to infliximab in human serum and plasma. The total-ADA workflow includes dissociation of infliximab–antibody complexes.
Neutralising Ab Kit
SHIKARI® T-CAP NAb Assay™
Infliximab Neutralising-Antibody ELISA
REF: INF-TCAP-NAb-REMI
Qualitative target-capture enzyme immunoassay for free neutralising antibodies to infliximab in serum and plasma, with positive, negative, cut-off and non-neutralising-antibody controls.
Biosimilar CT-P13 Family · 4 Kits
Infliximab biosimilar / Remsima® assays
Dedicated drug-level and ADA assays with separate Remsima® REF codes. These kits remain distinct in the comparison table, quote list and publication grouping.
Drug Levels Kit
SHIKARI® Q-REMS
Infliximab Biosimilar (Remsima®) ELISA
REF: INF-FD-REMS
Quantitative enzyme immunoassay for free infliximab biosimilar (Remsima®) in human serum and plasma, developed for the Cmin–Cmax research range.
Representative Standard Curve
Qualitative ADA Kit
SHIKARI® S-AIR
Anti-Infliximab Biosimilar (Remsima®) ELISA
REF: INF-QLS-REMS
Qualitative enzyme immunoassay for antibodies to infliximab biosimilar (Remsima®) in human serum and plasma. Results are interpreted against the assay cut-off.
Quantitative ADA Kit
SHIKARI® S-AIR w/confirmation
Quantitative Anti-Infliximab Biosimilar ELISA
REF: INF-QNS-REMS
Quantitative enzyme immunoassay for antibodies to infliximab biosimilar in human serum and plasma, supplied with confirmation and optimised with Remsima®.
Representative Standard Curve
Free / Total ADA Kit
SHIKARI® S-AIR TOTAL
Free/Total Anti-Infliximab Biosimilar ELISA
REF: INF-QNFT-REMS
Semi-quantitative assay for total and free antibodies to infliximab biosimilar in serum and plasma. The official product record identifies it as a Remsima®-focused total/free ADA format.
Technical Comparison
Kit Specifications at a Glance
Values below reproduce the current official product records. All ten kits use human serum or plasma, provide 96 tests, are stored at +4°C according to protocol and ship at room temperature.
Infliximab / Remicade® family
Six distinct REF codes| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-INFLIXI | INF-FD-REMI | Drug Levels | Infliximab (Remicade®) | Quantitative drug-level ELISA | 96 | 2–8°C |
| SHIKARI® QS-INFLIXI | INF-SPEC-INF | Specific Drug Levels | Free infliximab | Specific quantitative drug-level ELISA | 96 | 2–8°C |
| SHIKARI® Q-ATI | INF-QLS-REMI | Qualitative ADA | Anti-infliximab antibodies | Qualitative ADA ELISA | 96 | 2–8°C |
| SHIKARI® Q-ATI w/confirmation | INF-QNS-REMI | Quantitative ADA | Anti-infliximab antibodies | Quantitative ADA ELISA with confirmation | 96 | 2–8°C |
| SHIKARI® Q-ATI TOTAL | INF-QNFT-REMI | Free / Total ADA | Anti-infliximab antibodies | Free / total ADA ELISA | 96 | 2–8°C |
| SHIKARI® T-CAP NAb Assay™ | INF-TCAP-NAb-REMI | T-CAP NAb™ | Free neutralising antibodies to infliximab | Target Capture NAb ELISA | 96 | 2–8°C |
Infliximab biosimilar / Remsima® family
Four dedicated REF codes| Kit Name | Catalog Code | Type | Analyte | ELISA Format | Tests | Storage |
|---|---|---|---|---|---|---|
| SHIKARI® Q-REMS | INF-FD-REMS | Drug Levels | Infliximab biosimilar (Remsima®) | Quantitative drug-level ELISA | 96 | 2–8°C |
| SHIKARI® S-AIR | INF-QLS-REMS | Qualitative ADA | Anti-infliximab biosimilar antibodies | Qualitative ADA ELISA | 96 | 2–8°C |
| SHIKARI® S-AIR w/confirmation | INF-QNS-REMS | Quantitative ADA | Anti-infliximab biosimilar antibodies | Quantitative ADA ELISA with confirmation | 96 | 2–8°C |
| SHIKARI® S-AIR TOTAL | INF-QNFT-REMS | Free / Total ADA | Anti-infliximab biosimilar antibodies | Free / total ADA ELISA | 96 | 2–8°C |
Assay Selection
Keep the drug variant and analytical question explicit
This guide distinguishes assays by research purpose; it does not provide clinical decision rules. Quote requests retain the selected family and REF code.
| Research question | Remicade® / general family | Remsima®-optimised family |
|---|---|---|
| Quantitative free-drug level | Q-INFLIXI INF-FD-REMI | Q-REMS INF-FD-REMS |
| Specific quantitative free infliximab across both variants | QS-INFLIXI · INF-SPEC-INF Official record covers Remicade® and Remsima® | |
| Qualitative binding-ADA screen | Q-ATI INF-QLS-REMI | S-AIR INF-QLS-REMS |
| Quantitative binding ADA with confirmation | Q-ATI w/confirmation INF-QNS-REMI | S-AIR w/confirmation INF-QNS-REMS |
| Free and total ADA comparison | Q-ATI TOTAL INF-QNFT-REMI | S-AIR TOTAL INF-QNFT-REMS |
| Free neutralising-antibody detection | T-CAP NAb Assay™ INF-TCAP-NAb-REMI | |
Do not pool values from different assay configurations without an independently validated comparability plan. For Research Use Only (RUO). Not for use in diagnostic procedures.
Scientific Literature
Publications Using SHIKARI® Infliximab Kits 84
All journal publications below are drawn from the Matrix Biotek Publications library and are shown newest first. Records are included when the publication database identifies the biological drug and SHIKARI® product use.
Al-Jalehawi, Ahmad K., and Samer Imad Mohammed. "Fc-gamma receptors type3A (rs396991) genotyping for predicting infliximab efficacy and immunogenicity in ulcerative colitis: An observational study of Iraqi cohort." Medicine 105.9 (2026): e46119.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI TOTAL) Anti-Infliximab ELISA (Free/Total Ab)
Shibata, Hiroko, et al. "Evaluation of anti-drug antibodies against therapeutic monoclonal antibodies and related product in Japanese patients with rheumatoid arthritis and their clinical impact." European Journal of Pharmaceutical Sciences (2025): 107357
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (Q-GOL) Golimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Saleh, Hussein Hazim, Dheyaa J. Kadhim, and Raghad Jawad Hussein. "Therapeutic Drug Monitoring of Infliximab in Iraqi Patients with Moderate to Severe Ulcerative Colitis." Iraqi Journal of Pharmaceutical Sciences 34.3 (2025): 90-99.
Shikari® (Q-REMS) Infliximab biosimilar ELISAShikari® (S-AIR) Anti-Infliximab biosimilar ELISAShikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation
Kim, Yoon Zi, et al. "Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn’s disease." Scientific Reports 15.1 (2025): 23025.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Saleh, H. H., Khadim , D. J., & Hussein, R. J. (2024). Correlation between Therapeutic Drug Monitoring of Infliximab Serum Trough Levels and other Biomarkers in Iraqi Patients with Crohn’s Disease. Al-Rafidain Journal of Medical Sciences
Shikari® (Q-REMS) Infliximab biosimilar ELISAShikari® (S-AIR) Anti-Infliximab biosimilar ELISA w/confirmation
Nguyen, Anke L., et al. "Application of a Precision‐Dosing Model to a Real‐World Cohort of Patients on Infliximab Maintenance Therapy: Drug Usage and Cost Analysis." The Journal of Clinical Pharmacology 64.4 (2024): 399-409.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Akçadağ, Gülşah, et al. "Study on Cloning and Expression of TNF-α Variants in E. coli: Production, Purification, and Interaction with Anti-TNF-α Inhibitors." Protein and Peptide Letters 31.5 (2024): 395-408.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Shibata, Hiroko, et al. "Comparison of Immunochemical Reactions of Infliximab Innovator and Biosimilars on an Infliximab Detection Kit Used for Therapeutic Drug Monitoring." Biological and Pharmaceutical Bulletin 46.4 (2023): 621-629.
Shikari® (Q-INFLIXI) Infliximab ELISA
Rentsch, Clarissa A., et al. "Pharmacist-Driven Therapeutic Infliximab Monitoring at the Point of Care Using Rapidly Assessed Drug Levels in Patients with Inflammatory Bowel Disease." Therapeutic Drug Monitoring 45.3 (2023): 383-391.
Shikari® (Q-INFLIXI) Infliximab ELISA
Choi, So Yoon, et al. "Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn’s disease." Frontiers in Immunology 14 (2023): 1192827.
Shikari® (Q-INFLIXI) Infliximab ELISA
Cantarelli, Lorenzo, et al. "Definition of a therapeutic range for predicting long-term infliximab response in patients with inflammatory bowel disease." Medicina Clínica 160.3 (2023): 107-112.
Shikari® (Q-INFLIXI) Infliximab ELISA
Kita, Toshihiro, et al. "Adrenomedullin for biologic‐resistant Crohn's disease: A randomized, double‐blind, placebo‐controlled phase 2a clinical trial." Journal of Gastroenterology and Hepatology 37.11 (2022): 2051-2059.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Sakane, Hideo, et al. "Anti-drug antibodies and rheumatoid factor level in patients with rheumatoid arthritis using the infliximab biosimilar CT-P13." BMC rheumatology 6.1 (2022): 74.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Orts, Beatriz, et al. "Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn’s Disease." Frontiers in Pharmacology 12 (2022): 795272.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Maspero, Marianna, et al. "S79 Long Term Outcomes of Straight Ileoanal Anastomoses Converted to Ileal Pouch Anal Anastomoses." Official journal of the American College of Gastroenterology| ACG 117 (2022): S21.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Liu, Zheng, et al. "Timing of live attenuated vaccination in infants exposed to infliximab or adalimumab in utero: a prospective cohort study in 107 children." Journal of Crohn's and Colitis 16.12 (2022): 1835-1844.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Little, Robert D., et al. "De-escalation from dose-intensified anti-TNF therapy is successful in the majority of IBD patients at 12 months." Digestive Diseases and Sciences 67 (2022): 259-262.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Kawamoto, Ami, et al. "Serum Levels of Infliximab Biosimilar in a Child Delivered From a Mother Treated for Ulcerative Colitis." Inflammatory Bowel Diseases 28.8 (2022): 1298-1299.
Shikari® (Q-REMS) Infliximab biosimilar ELISA
Jeong, Tae Jong, et al. "Discontinuation of azathioprine could be considered in pediatric patients with Crohn’s disease who have sustained clinical and deep remission." Scientific Reports 12.1 (2022): 507.
Shikari® (Q-INFLIXI) Infliximab ELISA
Iwasaki, Takeshi, et al. "Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis." Frontiers in immunology 13 (2022): 901437.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-ETA) Etanercept ELISAShikari® (S-ATE) Anti-Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Нуриахметова, Т. Ю., et al. "Особенности ответа на инфликсимаб пациентов с воспалительными заболеваниями кишечника и анкилозирующим спондилитом." Русский медицинский журнал. Медицинское обозрение 5.2 (2021): 64-70.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmationShikari® (Q-ATI) Anti-Infliximab ELISA
Wu, Yang, et al. "Management Decisions in Crohn’s Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels." Crohn's & Colitis 360 3.3 (2021): otab042.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Ward, Mark G., et al. "Comparison of SB2-infliximab with originator-infliximab in the measurement of serum concentrations: a short communication." Therapeutic Drug Monitoring 43.5 (2021): 692-695.
Shikari® (Q-INFLIXI) Infliximab ELISA
Pękala, Anna, Rafał Filip, and David Aebisher. "Anti-drug antibodies in patients with inflammatory bowel diseases treated with biosimilar infliximab: A prospective cohort study." Journal of Clinical Medicine 10.12 (2021): 2653.
Shikari® (Q-REMS) Infliximab biosimilar ELISAShikari® (Q-ADA) Adalimumab ELISA
Pękala, Anna, and Rafał Filip. "Levels of Biosimilar Infliximab during and after Induction Treatment in Crohn’s Disease and Ulcerative Colitis—A Prospective Polish Population Study." Journal of Clinical Medicine 10.22 (2021): 5311.
Shikari® (Q-REMS) Infliximab biosimilar ELISA
MOHSEN, ENAS RIYADH, and NAAEL H. ALI. "IMPACT OF TH17/TREGFOXP3 CELLS RATIO ON RHEUMATOID ARTHRITIS PATIENTS RECEIVING ANTI TNF-THERAPY-." Journal of Duhok University 24.2 (2021): 90-102.
Shikari® (S-ATE) Anti-Etanercept ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Judit Szántó, Kata, et al. "Advances in the optimisation of therapeutic drug monitoring using serum, tissue and faecal anti-tumour necrosis factor concentration in patients with inflammatory bowel disease treated with TNF-α antagonists." Expert Opinion on Biological Therapy (2021).
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Alañón Pardo, M. M., et al. "Monitorización farmacocinética de terapias biológicas en enfermedad inflamatoria intestinal." Revista de la OFIL 31.1 (2021): 49-57.
Shikari® (S-ATA) Anti-Adalimumab ELISA w/confirmationShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmationShikari® (Q-ATI) Anti-Infliximab ELISA
Yokoyama, Yoko, et al. "Efficacy of granulocyte and monocyte adsorptive apheresis in patients with inflammatory bowel disease showing lost response to infliximab." Journal of Crohn's and Colitis 14.9 (2020): 1264-1273.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Seong, Gyeol, et al. "Changes in the intestinal microbiota of patients with inflammatory bowel disease with clinical remission during an 8-week infliximab infusion cycle." Microorganisms 8.6 (2020): 874.
Shikari® (Q-INFLIXI) Infliximab ELISA
Luber, Raphael P., et al. "Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease." Journal of Gastroenterology and Hepatology (2020).
Shikari® (Q-INFLIXI) Infliximab ELISA
Esatoglu, Sinem Nihal, et al. "Immunogenicity of infliximab among patients with behcet syndrome: a controlled study." Frontiers in Immunology 11 (2020): 618973.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Zapater, Pedro, et al. "Actual anti-TNF Trough levels relate to serum IL-10 in drug-responding patients with Crohn’s disease." Inflammatory bowel diseases 25.8 (2019): 1357-1366.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Vasudevan, Abhinav, et al. "Higher mucosal healing with tumor necrosis factor inhibitors in combination with thiopurines compared to methotrexate in Crohn’s disease." Digestive Diseases and Sciences 64 (2019): 1622-1631.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Patil, Abhishek, et al. "Anti‐drug antibodies and low serum trough infliximab levels correlate with disease activity measures in spondyloarthritis patients on an as‐needed infliximab treatment." International Journal of Rheumatic Diseases 22.9 (2019)
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Kang, Ben, et al. "Infliximab trough levels are associated with mucosal healing during maintenance treatment with infliximab in paediatric Crohn’s disease." Journal of Crohn's and Colitis 13.2 (2019): 189-197.
Shikari® (Q-INFLIXI) Infliximab ELISA
Flanagan, E., et al. "Stability of serum concentrations of infliximab and adalimumab across pregnancy in IBD." J Crohn’s Colitis 13 (2019): S449-S45050.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Duricova, Dana, et al. "Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation." Inflammatory bowel diseases 25.4 (2019): 789-796.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Choi, So Yoon, Ben Kang, and Yon Ho Choe. "Serum infliximab cutoff trough level values for maintaining hematological remission in pediatric inflammatory bowel disease." Gut and Liver 13.5 (2019): 541.
Shikari® (Q-INFLIXI) Infliximab ELISA
Pérez, Irene, et al. "Reliability evaluation of four different assays for therapeutic drug monitoring of infliximab levels." Therapeutic Advances in Gastroenterology 11 (2018): 1756284818783613.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Ohem, Jan, et al. "Evaluation of infliximab therapy in children with Crohn's disease using trough levels predictors." Digestive Diseases 36.1 (2018): 40-48.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Kolar, M., et al. "Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab." Age 28.4.1 (2018): 23-38.
Shikari® (Q-REMS) Infliximab biosimilar ELISA
Kang, Ben, et al. "Subtherapeutic infliximab trough levels and complete mucosal healing are associated with sustained clinical remission after infliximab cessation in paediatric-onset Crohn’s disease patients treated with combined immunosuppressive therapy." Journal of Crohn's and Colitis 12.6 (2018): 644-652.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Kang, Ben, et al. "Long-term outcomes after switching to CT-P13 in pediatric-onset inflammatory bowel disease: a single-center prospective observational study." Inflammatory bowel diseases 24.3 (2018): 607-616.
Shikari® (Q-INFLIXI) Infliximab ELISA
Bálint, Anita, et al. "Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis–results from multicenter observational cohort." Expert Opinion on Biological Therapy 18.11 (2018): 1181-1187.
Shikari® (Q-REMS) Infliximab biosimilar ELISA
Bolia, Rishi, et al. "Secondary loss of response to infliximab in pediatric Crohn disease: does it matter how and when we start?." Journal of pediatric gastroenterology and nutrition 66.4 (2018): 637-640.
Shikari® (Q-INFLIXI) Infliximab ELISA
Beswick, Lauren, et al. "Exploration of predictive biomarkers of early infliximab response in acute severe colitis: a prospective pilot study." Journal of Crohn's and Colitis 12.3 (2018): 289-297.
Shikari® (Q-INFLIXI) Infliximab ELISA
Raffáč, Štefan, et al. "Detection of anti-infliximab antibodies in Slovak IBD patients and its costs saving effect." Neuro Endocrinol Lett 38 (2017): 5-9.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Piñero, Paula, et al. "IL26 modulates cytokine response and anti-TNF consumption in Crohn’s disease patients with bacterial DNA." Journal of Molecular Medicine 95 (2017): 1227-1236.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Kolar, M., et al. "Infliximab biosimilar (Remsima™) in therapy of inflammatory bowel diseases patients: experience from one tertiary inflammatory bowel diseases centre." Digestive Diseases 35.1-2 (2017): 91-100.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Choi, So Yoon, et al. "Clinical use of measuring trough levels and antibodies against infliximab in patients with pediatric inflammatory bowel disease." Gut and Liver 11.1 (2017): 55.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Bálint, Anita, et al. "Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort." Expert opinion on drug safety 16.8 (2017): 885-890.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Aomori, Tohru, et al. "Suppression of infliximab antibody levels by azathioprine in patients with rheumatoid arthritis." Die Pharmazie-An International Journal of Pharmaceutical Sciences 72.2 (2017): 95-97.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Al-Karkhi, M. A., et al. "Association between HLA-DRB1 alleles and development of antibodies to infliximab in Iraqi patients with rheumatoid arthritis." research Journals od medicine and clinical sciences. Basic Res. J. Med. Clin. Sci 6.3 (2017): 30-35.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Song, Won Jae, et al. "Adalimumab treatment in pediatric-onset Crohn's disease patients after infliximab failure: A single center study." Pediatric Gastroenterology, Hepatology & Nutrition 19.2 (2016): 116-122.
Shikari® (Q-ATI) Anti-Infliximab ELISA
Malíčková, Karin, et al. "Serum trough infliximab levels: a comparison of three different immunoassays for the monitoring of CT-P13 (infliximab) treatment in patients with inflammatory bowel disease." Biologicals 44.1 (2016): 33-36.
Shikari® (Q-INFLIXI) Infliximab ELISA
Kui, Róbert, et al. "Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)‐α level and the efficacy of TNF‐inhibitor therapy in psoriasis." The Journal of Dermatology 43.9 (2016): 1018-1023.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Kang, Ben, et al. "Mucosal healing in paediatric patients with moderate-to-severe luminal Crohn’s disease under combined immunosuppression: escalation versus early treatment." Journal of Crohn's and Colitis 10.11 (2016): 1279-1286.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Julsgaard, Mette, et al. "Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection." Gastroenterology 151.1 (2016): 110-119.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Hayashi, Satoko, et al. "Early prognostic factors associated with the efficacy of infliximab treatment for patients with rheumatoid arthritis with inadequate response to methotrexate." Rheumatology and therapy 3 (2016): 155-166.
Shikari® (Q-INFLIXI) Infliximab ELISA
Gutiérrez, Ana, et al. "Gut bacterial DNA translocation is an independent risk factor of flare at short term in patients with Crohn’s disease." Official journal of the American College of Gastroenterology| ACG 111.4 (2016): 529-540.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Gibellini, Lara, et al. "Anti-TNF-α drugs differently affect the TNFα-sTNFR system and monocyte subsets in patients with psoriasis." PLoS One 11.12 (2016): e0167757.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ETA) Etanercept ELISAShikari® (S-ATE) Anti-Etanercept ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Farkas, Klaudia, et al. "Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis." Journal of Crohn's and Colitis 10.11 (2016): 1273-1278.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Lee, Yoo Min, et al. "Infliximab “top-down” strategy is superior to “step-up” in maintaining long-term remission in the treatment of pediatric Crohn disease." Journal of pediatric gastroenterology and nutrition 60.6 (2015): 737-743.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Juanola, Oriol, et al. "Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn’s disease." Journal of gastroenterology 50 (2015): 758-768.
Shikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Al-Karkhi, Mohammed A., Muhammed M. Al-Ani, and Nizar A. Jassim. "Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis." Journal of the Faculty of Medicine Baghdad 57.3 (2015): 241-243.
Shikari® (Q-ATI) Anti-Infliximab ELISA
Al-Karkhi, Mohammed A., et al. "Correlation between Anti-infliximab and Anti-CCP Antibodies Development in Patients with Rheumatoid Arthritis Treated with Infliximab in Baghdad Teaching Hospital." IOSR Journal of Dental and Medical Sciences 14.11 (2015)
Shikari® (Q-ATI) Anti-Infliximab ELISA
Pallagi-Kunstár, Éva, et al. "Utility of serum TNF-α, infliximab trough level, and antibody titers in inflammatory bowel disease." World Journal of Gastroenterology: WJG 20.17 (2014): 5031.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Krajcovicova, Anna, et al. "Delayed hypersensitivity reaction after initial dose of infliximab: a case report." European Journal of Gastroenterology & Hepatology 26.4 (2014): 485-487.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Kozub, Peter, et al. "Management of infliximab treated patients with psoriasis based on infliximab plasma levels and antibodies to infliximab." J Clin Exp Dermatol Res 5 (2014): 214.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Gutiérrez, Ana, et al. "Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease." Gut 63.2 (2014): 272-280.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Grosen, Anne, et al. "Infliximab concentrations in the milk of nursing mothers with inflammatory bowel disease." Journal of Crohn's and Colitis 8.2 (2014): 175-176.
Shikari® (Q-INFLIXI) Infliximab ELISA
Bortlik, Martin, et al. "Impact of anti–tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children." Inflammatory bowel diseases 20.3 (2014): 495-501.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Takahashi, Hidetoshi, et al. "Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis." The Journal of dermatology 40.1 (2013): 39-42.
Shikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Malíčková, Karin, et al. "Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases." Autoimmunity Highlights 4 (2013): 27-32.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Bortlik, Martin, et al. "Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-α therapy during pregnancy: three-center study." Scandinavian journal of gastroenterology 48.8 (2013): 951-958.
Shikari® (Q-ADA) Adalimumab ELISAShikari® (Q-INFLIXI) Infliximab ELISA
Bortlik, Martin, et al. "Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease." Journal of Crohn's and Colitis 7.9 (2013): 736-743.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Molnár, T., et al. "Importance of trough levels and antibody titers on the efficacy and safety of Infliximab therapy in inflammatory bowel disease." Zeitschrift für Gastroenterologie 50.05 (2012): A53.
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Lee, Yun Seok, et al. "Efficacy of early infliximab treatment for pediatric Crohn's disease: a three-year follow-up." Pediatric gastroenterology, hepatology & nutrition 15.4 (2012): 243-249.
Shikari® (Q-ATI) Anti-Infliximab ELISA
Kato, Shingo, et al. "Elevated serum IgE prior to acute severe infusion reaction during infliximab maintenance therapy in a crohn's disease patient." Inflammatory Bowel Diseases 17.12 (2011): E156-E157.
Shikari® (Q-ATI) Anti-Infliximab ELISA w/confirmation
Adişen, Esra, et al. "Anti‐infliximab antibody status and its relation to clinical response in psoriatic patients: a pilot study." The Journal of dermatology 37.8 (2010): 708-713.
Shikari® (Q-ATI) Anti-Infliximab ELISA
M Zviaglova and others, P453 The significance of the concentration of antibodies to infliximab on the frequency of loss of response when alternating the original drug infliximab and its biosimilar in patients with ulcerative colitis.
Shikari® (Q-INFLIXI) Infliximab ELISA
Evaluation of selected serum biomarkers levels in response to the infliximab reference product (Remicade®) versus its biosimilar (Remsima®) in a sample of ulcerative colitis patients: a cross-sectional study
Shikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI TOTAL) Anti-Infliximab ELISA (Free/Total Ab)
Efficacy of tumor necrosis factor-α inhibitors in the treatment of various immunoinflammatory diseases:focus on immunogenicity/Эффективность ингибиторов фактора некроза опухоли α в лечении различных иммуновоспалительных заболеваний:фокус на иммуногенность
Shikari® (Q-ADA) Adalimumab ELISAShikari® (S-ATA) Anti-Adalimumab ELISAShikari® (Q-CERT) Certolizumab ELISAShikari® (Q-INFLIXI) Infliximab ELISAShikari® (Q-ATI) Anti-Infliximab ELISA
Keep the assay family clear in every request
Add individual REF codes, one complete family, or the full ten-kit portfolio to the shared Quote List. Matrix Biotek will provide current regional availability, documentation, quotation and delivery information through its European headquarters in Barcelona.